Breaking
Tau-Targeting Therapy Slows Alzheimer’s Decline Over Two Years
Longevity Lab

Tau-Targeting Therapy Slows Alzheimer’s Decline Over Two Years

Zoe Cooper · November 19, 2026

Tau-targeting therapy shows continued benefits in slowing clinical decline in patients with early Alzheimer's disease over two years.

★

Longevity Lab

Longevity Lab →
+

More News

Tau-Targeting Therapy Slows Alzheimer’s Decline Over Two Years
Longevity Lab

Tau-targeting therapy shows continued benefits in slowing clinical decline in patients with early Alzheimer's disease over two years.

November 19, 2026
US Loses Measles Elimination Status
Gut Check

US loses measles elimination status due to a significant increase in measles cases, with over 5,400 cases reported…

November 18, 2026
U.S. Measles Outbreaks Trigger Alarming Rise in Congenital Cases
Recovery Mode

U.S. measles outbreaks since 2025 have triggered a concerning rise in congenital measles cases among infants, with 13…

November 17, 2026
US tariffs hit smaller drugmakers too
Recovery Mode

US tariffs hit smaller drugmakers too with potential rates climbing as high as 100%.

November 16, 2026
NIH reorganizes clinical trial funding system
Mind Matters

NIH develops unified approach to clinical trial funding, streamlining submission guidelines for researchers with clinical trial funding.

November 14, 2026
FDA requires new vision loss warning for GLP-1 drugs
Body Signals

The FDA requires a new warning about vision loss for GLP-1 drugs after a review of clinical trials…

November 13, 2026
Compass Files FDA NDA for Psilocybin Depression Treatment
Body Signals

Compass Pathways has filed an FDA NDA for its psilocybin depression treatment, COMP360, after two Phase 3 trials…

November 12, 2026
PROTAC drugs face major formulation hurdles
Recovery Mode

Proteolysis-targeting chimeras face major formulation hurdles that may delay their approval. Learn about the challenges facing PROTAC drugs…

November 11, 2026
AI-designed TEAD inhibitor shows tumor shrinkage
Recovery Mode

Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control…

November 10, 2026
Hepatitis C drug shows promise but misses key patient groups
Longevity Lab

AbbVie’s Maviret achieves 96% cure rate for acute hepatitis C but excludes key patient groups, raising access and…

November 9, 2026